Journal article

Update on emerging drugs for sarcopenia - age-related muscle wasting

Gordon S Lynch

EXPERT OPINION ON EMERGING DRUGS | TAYLOR & FRANCIS LTD | Published : 2008

Abstract

UNLABELLED: Sarcopenia - the progressive loss of muscle mass with advancing age is characterised by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Frail elders often require assistance for accomplishing even basic tasks of independent living, and they are also at increased risk of serious injury from sudden falls and subsequent fractures. Since these age-related changes are largely attributed to the complex interaction of factors affecting neuromuscular transmission, muscle architecture, fibre composition, excitation-contraction coupling, and metabolism, the..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Australian Research Council Discovery


Awarded by National Health and Medical Research Council of Australia


Awarded by Muscular Dystrophy Association (USA)


Funding Acknowledgements

The author is grateful for research grant support from the Australian Research Council Discovery-Project funding scheme (DP0665071, DP0772781), National Health and Medical Research Council of Australia (454561, 509313, 566818, 566820), Muscular Dystrophy Association (USA, 4167), Association Francaise contre les Myopathies, Pfizer, Inc. (USA), E Hoffmann-La Roche Ltd. (Switzerland) and Merck & Co., Inc. (USA).